eli lilly and company zepbound - Search News

News

Eli Lilly Vows to Make Weight-Loss Pill in U.S.

The Motley Fool on MSN · 7h

Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a diabetes treatment since 2019. It's an orally available version of semaglutide, which is the same active ingredient in Ozempic and Wegovy.

CBS News on MSN · 1d

Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

USA TODAY on MSN · 1d

Eli Lilly announces trial results of new weight loss, diabetes pill; stock booms

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

22h

Everything to know about the new weight loss pill that works as well as Ozempic — and when you can get it

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

1d

Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

24/7 Wall St.22h

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (April 2025)

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results